Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on ...

Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

Evonik’s latest layoffs are tied to discontinuing production of keto acids in Hanau, Germany, by the end of next year.

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Turnstone is shifting resources to focus on clinical advancement of its selected tumor-infiltrating lymphocyte therapy as ...

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...